Abstract
The proteasome inhibition has been proved to be effective in the treatment of multiple myeloma and other malignancies. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on immune cells, such as T cells, B cells and DCs. Therefore, proteasome inhibition, through the utilization of small molecule drugs like bortezomib, could be used therapeutically to modulate immune responses in transplantation. In the current review, we discuss the emerging data, both preclinical and clinical, of using proteasome inhibition in treating complications of transplantation, such as antibody-mediated organ rejection (AMR) and graft-versus-host disease (GVHD). The therapy based on proteasome inhibition may present substantial opportunities as new therapeutic paradigms in transplantation.
Keywords: Immunosuppression, proteasome, proteasome inhibitors, T cells, bortezomib, transplantation, B cells, DCs.
Current Pharmaceutical Design
Title:Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib
Volume: 19 Issue: 18
Author(s): Yong Liang and Haiyan Liu
Affiliation:
Keywords: Immunosuppression, proteasome, proteasome inhibitors, T cells, bortezomib, transplantation, B cells, DCs.
Abstract: The proteasome inhibition has been proved to be effective in the treatment of multiple myeloma and other malignancies. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on immune cells, such as T cells, B cells and DCs. Therefore, proteasome inhibition, through the utilization of small molecule drugs like bortezomib, could be used therapeutically to modulate immune responses in transplantation. In the current review, we discuss the emerging data, both preclinical and clinical, of using proteasome inhibition in treating complications of transplantation, such as antibody-mediated organ rejection (AMR) and graft-versus-host disease (GVHD). The therapy based on proteasome inhibition may present substantial opportunities as new therapeutic paradigms in transplantation.
Export Options
About this article
Cite this article as:
Liang Yong and Liu Haiyan, Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/13816128113199990308
DOI https://dx.doi.org/10.2174/13816128113199990308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multitarget Antithrombotic Drugs
Current Topics in Medicinal Chemistry The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets The Role of Coronary Physiology in Contemporary Percutaneous Coronary Interventions
Current Cardiology Reviews Current Antiviral Therapy for Chronic Hepatitis C Including Liver Transplantation and Hepatic Resection
Current Medicinal Chemistry - Anti-Infective Agents Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Endocrine, Metabolic & Immune Disorders - Drug Targets The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Pexelizumab and its Role in the Treatment of Myocardial Infarction and in Coronary Artery Bypass Graft Surgery: A Review
Recent Patents on Cardiovascular Drug Discovery Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued)